The daily doses to be administered should be those that are approved by the regulatory authorities and indicated in the information leaflets by the pharmaceutical companies for the respective application forms, in the case of anti-CD3 for treatment of T1DM and in the case of anti-TNF-α for the treatment of other autoimmune diseases such as rheumatoid arthritis. This evidence concerns the gene TNF and type 1 diabetes mellitus.